奥英妥珠单抗单药治疗儿童复发/难治性急性淋巴细胞白血病:II期临床试验结果
该II期试验评估奥英妥珠单抗单药治疗1-18岁复发/难治性CD22阳性B细胞急性淋巴细胞白血病患者,给药剂量为RP2D 1.8 mg/m2。研究达到主要终点,估计总缓解率为81.5%(95%CI: 61.9-93.7%),81.8%(18/22)的缓解者达到微小残留病阴性。中位随访16个月,1年无事件生存率为36.7%,总生存率为55.1%。
要点
- 奥英妥珠单抗单药在该儿童复发/难治性B-ALL人群中有效,估计ORR为81.5%。
- 81.8%(18/22)的缓解者达到MRD阴性。
- 7例发生肝窦阻塞综合征,尤其在InO治疗后接受HSCT时风险最相关。
核心结论
- 奥英妥珠单抗在该儿童复发/难治性CD22阳性B-ALL人群中有效。
- 最相关的风险是肝窦阻塞综合征的发生,尤其是奥英妥珠单抗治疗后接受HSCT时。
研究设计与样本
- II期临床试验,采用单阶段设计,ORR≤30%定义为不 promising,ORR>55%为预期值。
- 需招募25例患者以达到80%把握度(显著性水平0.05)。
- 实际入组32例,治疗28例,可评估缓解27例。
- 患者年龄1-18岁,复发/难治性CD22阳性B细胞急性淋巴细胞白血病,给药剂量为RP2D 1.8 mg/m2。
主要发现
- 估计ORR为81.5%(95%CI: 61.9-93.7%),研究达到主要终点。
- 81.8%(18/22)的缓解受试者为MRD阴性。
- 存活者中位随访16个月(IQR: 14.49-20.07)。
- 1年无事件生存率为36.7%(95%CI: 22.2-60.4%),总生存率为55.1%(95%CI: 39.1-77.7%)。
- 18例患者接受巩固治疗(HSCT和/或CAR-T细胞治疗);7例发生肝窦阻塞综合征。
关键数值与推荐
- MRD阴性似乎与体外calicheamicin敏感性相关,但与CD22表面表达、饱和度或内化无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1-18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m2. Using a single-stage design, with an overall response rate (ORR) ≤ 30% defined as not promissing and ORR > 55% as expected, 25 patients needed to be recruited to achieve 80% power at 0.05 significance level. Thirty-two patients were enrolled, 28 were treated, 27 were evaluable for response. The estimated ORR was 81.5% (95%CI: 61.9-93.7%), and 81.8% (18/22) of the responding subjects were minimal residual disease (MRD) negative. The study met its primary endpoint. Median follow up of survivors was 16 months (IQR: 14.49-20.07). One year Event Free Survival was 36.7% (95% CI: 22.2-60.4%), and Overall Survival was 55.1% (95% CI: 39.1-77.7%). Eighteen patients received consolidation (with HSCT and/or CAR T-cells therapy). Sinusoidal obstructive syndrome (SOS) occurred in seven patients. MRD negativity seemed correlated to calicheamicin sensitivity in vitro, but not to CD22 surface expression, saturation, or internalization. InO was effective in this population. The most relevant risk was the occurrence of SOS, particularly when InO treatment was followed by HSCT.
引用
- Pennesi E, Michels N, Brivio E, et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022. PMID: 35468945. doi:10.1038/s41375-022-01576-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。